Alphamab Oncology Dirección
Dirección controles de criterios 2/4
Alphamab Oncology's CEO is Ting Xu, appointed in Nov 2008, has a tenure of 6.67 years. total yearly compensation is CN¥6.88M, comprised of 95.2% salary and 4.8% bonuses, including company stock and options. directly owns 33.06% of the company’s shares, worth HK$1.23B. The average tenure of the management team and the board of directors is 5.8 years and 5 years respectively.
Información clave
Ting Xu
Chief Executive Officer (CEO)
CN¥6.9m
Compensación total
Porcentaje del salario del CEO | 95.2% |
Permanencia del CEO | 16yrs |
Participación del CEO | 33.1% |
Permanencia media de la dirección | 5.8yrs |
Promedio de permanencia en la Junta Directiva | 5yrs |
Actualizaciones recientes de la dirección
Recent updates
Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable
Sep 30Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding
Jun 20Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up
May 06Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking
Mar 13Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price
Jan 17Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch
May 21Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts
Mar 01Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?
Oct 04Is Alphamab Oncology (HKG:9966) A Risky Investment?
May 21Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt
Oct 05Is Alphamab Oncology (HKG:9966) Using Too Much Debt?
May 05Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -CN¥216m |
Mar 31 2024 | n/a | n/a | -CN¥213m |
Dec 31 2023 | CN¥7m | CN¥7m | -CN¥211m |
Sep 30 2023 | n/a | n/a | -CN¥214m |
Jun 30 2023 | n/a | n/a | -CN¥218m |
Mar 31 2023 | n/a | n/a | -CN¥272m |
Dec 31 2022 | CN¥7m | CN¥6m | -CN¥326m |
Sep 30 2022 | n/a | n/a | -CN¥309m |
Jun 30 2022 | n/a | n/a | -CN¥292m |
Mar 31 2022 | n/a | n/a | -CN¥352m |
Dec 31 2021 | CN¥7m | CN¥5m | -CN¥412m |
Sep 30 2021 | n/a | n/a | -CN¥502m |
Jun 30 2021 | n/a | n/a | -CN¥592m |
Mar 31 2021 | n/a | n/a | -CN¥510m |
Dec 31 2020 | CN¥5m | CN¥4m | -CN¥428m |
Sep 30 2020 | n/a | n/a | -CN¥652m |
Jun 30 2020 | n/a | n/a | -CN¥877m |
Mar 31 2020 | n/a | n/a | -CN¥851m |
Dec 31 2019 | CN¥5m | CN¥3m | -CN¥833m |
Compensación vs. Mercado: Ting's total compensation ($USD969.67K) is above average for companies of similar size in the Hong Kong market ($USD399.57K).
Compensación vs. Ingresos: Ting's compensation has increased whilst the company is unprofitable.
CEO
Ting Xu (51 yo)
16yrs
Permanencia
CN¥6,877,000
Compensación
Dr. Ting Xu, Ph D., serves Chief Executive Officer at Alphamab Oncology since October 1, 2018. He Founded Alphamab Oncology in November 2008.Dr. Xu serves as Executive Director at Alphamab Oncology since...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Founder | 16yrs | CN¥6.88m | 33.06% HK$ 1.2b | |
VP of Corporate Operations & Executive Director | 6.1yrs | CN¥2.97m | sin datos | |
Vice President of Government Affairs & Public Relations | 5.8yrs | sin datos | sin datos | |
Senior Vice President of Business Development | 6.5yrs | sin datos | sin datos | |
Chief Commercial Officer | 3yrs | sin datos | sin datos | |
Joint Company Secretary | 4.3yrs | sin datos | sin datos | |
Joint Company Secretary | less than a year | sin datos | sin datos |
5.8yrs
Permanencia media
51.5yo
Promedio de edad
Equipo directivo experimentado: 9966's management team is seasoned and experienced (5.8 years average tenure).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Founder | 6.7yrs | CN¥6.88m | 33.06% HK$ 1.2b | |
VP of Corporate Operations & Executive Director | 6.1yrs | CN¥2.97m | sin datos | |
Independent Non-Executive Director | 5yrs | CN¥396.00k | sin datos | |
Non-Executive Director | less than a year | sin datos | 0.11% HK$ 4.0m | |
Member of Scientific Advisory Board | no data | sin datos | sin datos | |
Member of Scientific Advisory Board | no data | sin datos | sin datos | |
Independent Non-Executive Director | 5yrs | CN¥396.00k | sin datos | |
Member of Scientific Advisory Board | no data | sin datos | sin datos | |
Chairman of Scientific Advisory Board | no data | sin datos | sin datos | |
Independent Non-Executive Director | 3.3yrs | CN¥378.00k | sin datos |
5.0yrs
Permanencia media
55yo
Promedio de edad
Junta con experiencia: 9966's board of directors are considered experienced (5 years average tenure).